Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study.
Elisa GobbiniR ChiariP PizzutilloP BordiL GhilardiS PilottoG OsmanF CappuzzoF CecereF RiccardiV ScottiO MartelliG BorraE MaielloA RossiP GrazianoV GregorcC CasartelliC SergiA Del ConteA DelmonteC BareggiD CortinovisP RizzoF TabbòG RossiE BriaD GalettaM TiseoM Di MaioS NovelloPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2019)
The sequential administration of crizotinib and a new generation ALKis provided a remarkable clinical benefit in this real-life population, being an interesting option to consider in selected patients.